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Pulmonary  arterial  hypertension  (PAH)  is  a 
vascular disease that is largely restricted to small 
pulmonary arteries (PAs). PAH occurs in rare 
idiopathic and familial forms, but is more com-
monly part of a syndrome associated with con-
nective tissue diseases, anorexigen use, HIV, or 
congenital  heart  disease.  Many  abnormalities 
contribute to this syndrome of obstructed, con-
stricted small PAs. This includes abnormalities 
in the blood content of some neurotransmitters 
and cytokines, namely increases in serotonin, 
IL-6,  platelet-derived  growth  factor  (PDGF), 
and endothelin (Stewart et al., 1991; Christman 
et al., 1992; Steudel et al., 1997; Perros et al., 
2008). The media is also characterized by an   
increased activation of the nuclear factor of   
activated T cells (NFAT), leading to increased 
[Ca2+]i-mediated PA smooth muscle cell (PASMC)   
proliferation  and  decreased  mitochondrial- 
dependent  apoptosis  (Bonnet  et  al.,  2006, 
2007b). Finally, the adventitia is infiltrated with 
inflammatory cells and exhibits metalloprotease 
activation (Humbert et al., 2004). Despite re-
cent therapeutic advances such as endothelin-1 
receptor blockers (e.g., Bosentan; Dupuis and 
Hoeper, 2008), type 5 phosphodiesterase inhib-
itors (e.g., sildenafil; Li et al., 2007), or PDGF 
receptor blockers (e.g., imatinib; Ghofrani et al., 
2005), mortality rates remain high (Archer and 
Rich, 2000). Moreover, the fact that the PAH 
phenotype  is  preserved  in  cultured  PASMCs 
isolated  from  PAH  patients  suggests  that  the 
PAH phenotype is sustained independently of 
the circulating growth factors or agonists but 
requires genetic remodeling processes (Yildiz, 
2009; Dumas de la Roque et al., 2010). Over 
the past 10 yr, genetic research on PAH has led 
to the discovery of mutations in the BMPR2 
(bone  morphogenetic  receptor-2)  gene  in  at  least 
50% of familial PAH patients, and its down-
regulation is recognized as a hallmark of PAH 
(Tada et al., 2007; Zakrzewicz et al., 2007).   
Recently,  BMPR2  down-regulation  in  human 
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Pulmonary arterial hypertension (PAH) is characterized by enhanced proliferation and 
reduced apoptosis of pulmonary artery smooth muscle cells (PASMCs). Because microRNAs 
have been recently implicated in the regulation of cell proliferation and apoptosis, we 
hypothesized that these regulatory molecules might be implicated in the etiology of PAH.  
In this study, we show that miR-204 expression in PASMCs is down-regulated in both 
human and rodent PAH. miR-204 down-regulation correlates with PAH severity and  
accounts for the proliferative and antiapoptotic phenotypes of PAH-PASMCs. STAT3 acti-
vation suppresses miR-204 expression, and miR-204 directly targets SHP2 expression, 
thereby SHP2 up-regulation, by miR-204 down-regulation, activates the Src kinase and 
nuclear factor of activated T cells (NFAT). STAT3 also directly induces NFATc2 expression. 
NFAT and SHP2 were needed to sustain PAH-PASMC proliferation and resistance to apop-
tosis. Finally, delivery of synthetic miR-204 to the lungs of animals with PAH significantly 
reduced disease severity. This study uncovers a new regulatory pathway involving miR-204 
that is critical to the etiology of PAH and indicates that reestablishing miR-204 expression 
should be explored as a potential new therapy for this disease.
© 2011 Courboulin et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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role of miR-204 in the etiology of PAH. Interestingly, using 
in silico and microarray gene expression analyses, we observed 
that among the 461 predicted targets of miR-204 (TargetScan 
5.1), only 165 were increased by artificial miR-204 inhibition 
in control human PASMCs (n = 2 patients; Fig. S1 C). In ac-
cordance with the pro-proliferative and antiapoptotic pheno-
types seen in PAH, several Src–STAT3- and NFAT-related 
genes were identified (Fig. S1 C).
miR-204 expression is decreased in human PAH  
and correlates with PAH severity
To investigate the expression pattern of miR-204 in normal 
and pulmonary hypertensive lungs, we examined miR-204 
expression levels in (a) lung biopsies from 8 individuals with 
nonfamilial PAH compared with biopsies from 8 individuals 
without pulmonary hypertension, (b) lungs from 6 mice with 
hypoxia-induced pulmonary hypertension compared with 5 
control littermates, and (c) lungs from 5 rats with monocrota-
line (MCT)-induced pulmonary hypertension compared with 
10 control littermates (Fig. 1 A). We found decreased levels of 
miR-204 in human and rodent pulmonary hypertensive lung 
tissues compared with normotensive lung samples. To charac-
terize whether down-regulated miR-204 levels were specific   
to the lung in rats with pulmonary hypertension, we com-
pared organ-specific levels of miR-204 between normal 
and pulmonary hypertensive rats (Fig. 1 B). Even if we were 
able to detect minimal amounts of miR-204 in most organs, 
miR-204 levels were only down-regulated in the lung and 
PAs but not in the aorta, liver, heart, and kidney in rats   
3  wk  after  MCT  injection  (pulmonary  hypertensive  rats) 
compared with non–pulmonary hypertensive rats (Fig. 1 B).
To test whether miR-204 down-regulation correlated with 
disease progression, we studied humans, mice, and rats with 
varying degrees of PAH. In both human subjects and rodents, 
miR-204 levels in the lung correlated directly with the severity 
of PAH, as measured by pulmonary vascular resistance in hu-
mans and mean PA pressure in rodents (Fig. 1 C). Our results 
indicate that levels of miR-204 correlate with the severity of 
PAH in humans and experimental pulmonary hypertension.
miR-204 is confined to PASMCs in the lung
To determine the lung distribution of miR-204, miR-204 
expression was measured by qRT-PCR in rat bronchi, veins, 
and PAs. Our results indicate that miR-204 is in majority ex-
pressed within PAs but not in veins or bronchi tissue (Fig. S2 A). 
To determine the cell type distribution of miR-204 within 
PAs,  miR-204  expression  was  measured  in  both  cultured 
(passage 3 and less) human PASMCs and PA endothelial cells 
(PAECs). Our results indicate that within PAs, miR-204 is 
mostly confined to the PASMCs as control-cultured PASMCs 
expressed seven times more miR-204 compared with control 
PAECs (Fig. S2 B).
miR-204 expression level is a potent biomarker for PAH
Finally, because miRNAs are currently used in humans as   
a biomarker of cancer (Ferracin et al., 2010), to further   
PASMCs has been linked to the activation of both the tyro-
sine kinase Src (Wong et al., 2005) and a STAT3/miR-17-92 
microRNA (miRNA) secondary to IL-6 exposure, suggest-
ing  the  implication  of  miRNAs  in  the  etiology  of  PAH 
(Brock et al., 2009).
miRNAs are small noncoding RNAs (21–23 nt) that are 
now known to be important regulators of gene expression. 
They form imperfect RNA–RNA duplexes and use their 
seed  region  to  interact  with  messenger  RNAs  (mRNAs), 
mainly in the 3 untranslated region (UTR; Khan et al., 2009). 
This interaction leads to a negative posttranscriptional regula-
tion  of  the  relevant  mRNAs.  Recently,  misexpression  of 
miRNAs has been implicated in many cardiovascular diseases, 
including pulmonary hypertension (Latronico and Condorelli, 
2009; Mishra et al., 2009; Zhang, 2009; Caruso et al., 2010), 
but their molecular role in these pathologies has not been 
uncovered yet.
RESULTS
miR-204 is aberrantly expressed in human PAH-PASMCs
To determine whether miRNAs are aberrantly expressed in 
human PAH, PASMCs were isolated from distal PAs of two 
nonfamilial PAH patients (two idiopathic PAH [iPAH] pa-
tients A  and  B;  based  on  the World  Health  Organization 
[WHO] classification) and two control patients (A and B) and 
cultured as previously described (passage 3 and less; McMurtry 
et al., 2005). The expression of 377 different miRNAs was 
measured.  Seven  miRNAs  were  aberrantly  expressed  in 
PAH-PASMCs compared with control PASMCs (miR-204, 
-450a, -145, -302b, -27b, -367, and -138; Fig. S1 A). Among 
them, only the miR-204 level was down-regulated (Fig. S1 A). 
miR-204  down-regulation  between  control  versus  PAH 
was confirmed by quantitative RT-PCR (qRT-PCR) in 
PASMCs isolated from three PAH (all from group 1 based on 
WHO classification patients A–C) compared with control 
PASMCs isolated from five control patients (A–E). Note that 
no significant differences in miR-204 expression was found 
among the control patients and the PAH patients (Fig. S1 B). 
Therefore, for the rest of the study, all five control PASMC 
and the three PAH-PASMC cell lines were used for every 
cell-based experiment.
Interestingly, in retinal epithelial cells and several cancer 
cells, miR-204 down-regulation has been associated with en-
hanced cell proliferation and membrane potential depolariza-
tion (Lee et al., 2010; Wang et al., 2010), which are both 
aspects  also  seen  in  PAH-PASMCs  (Bonnet  et  al.,  2006, 
2007b). We recently showed in several cancer cells and PAH-
PASMCs (Bonnet et al., 2007a,b) that this pro-proliferative 
phenotype was associated in part with the activation of the 
Src–STAT3 (accounting for BMPR2 down-regulation; Wong   
et al., 2005) and NFAT pathways (Bonnet et al., 2007b). This 
suggests a putative link between miR-204 down-regulation, 
NFAT  activation,  and  cell  proliferation. Thus,  miR-204  is 
likely implicated in PAH, and a role in the sustainability of the 
PAH-PASMC pro-proliferative and antiapoptotic phenotype 
is possible. Therefore, the current study will be focused on the JEM VOL. 208, March 14, 2011 
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Diminution of miR-204 level promotes PASMC proliferation 
and resistance to apoptosis
To study the effect of miR-204 on PASMC proliferation and 
apoptosis  in  vitro,  cultured  human  PAH-PASMCs  were   
either exposed to 10% FBS to promote proliferation or 0.1% 
FBS to promote apoptosis (Bonnet et al., 2007b). When com-
pared with control PASMCs containing a high level of miR-
204, PAH-PASMCs displayed a higher cell proliferation rate 
and resistance to induced apoptosis (Fig. 2 A). The implication   
of miR-204 in regulating PASMC proliferation and apoptosis 
was confirmed in control PASMCs, in which miR-204 inhi-
bition increased proliferation and resistance to apoptosis to 
levels similar to those seen in PAH-PASMCs (Fig. 2 A).
confirm the implication of miR-204 in PAH, we measured 
miR-204 expression level in human buffy coat isolated from 
non–pulmonary  hypertensive  patients  and  patients  with 
PAH (Table S1). We previously showed that human PAH-
PASMCs and cells from the buffy coat of PAH patients have 
a lot of similarities in term of activated pathways. For ex-
ample, both have activated NFAT (Bonnet et al., 2007b); 
thus, miR-204 expression in the buffy coat could parallel 
miR-204 expression in PASMCs. Indeed, as in PAH-PASMCs, 
miR-204 expression was significantly decreased in patients 
with PAH (Fig. S2 C). This result is of a great clinical interest 
as it confirms the implication of miR-204 in PAH and suggests 
that miR-204 can become a reliable biomarker of PAH.
Figure 1.  Correlation between miR-204 expression and PAH severity. (A) miR-204 is decreased in human, mouse, and rat PAH lungs. qRT-PCR analysis of 
miR-204 expression in human lungs with PAH (n = 8), mouse lungs with hypoxia-induced pulmonary hypertension (n = 6), and rat lungs with MCT-induced pul-
monary hypertension (n = 5) compared with human (n = 8), mouse (n = 10) and rat (n = 5) control (Ctrl) lungs. (B) miR-204 is mainly expressed in the distal PAs. 
qRT-PCR analysis of miR-204 expression in several rat organs with MCT-induced pulmonary hypertension (n = 5) compared with control rats (n = 5). (C) miR-204 
down-regulation correlates with PAH severity. qRT-PCR analysis of miR-204 expression in the lungs from healthy subjects (n = 8) and from patients with varying 
severity of PAH (n = 3), in mouse lungs with varying severity of hypoxia-induced pulmonary hypertension (n = 3), and in rat lungs with varying severity of MCT-
induced pulmonary hypertension (n = 3) compared with control animals (n = 5 for both rats and mice; n = 3 experiments per patient or per animal for each pul-
monary vascular resistance [PVR] or mean pulmonary arterial pressure [PAP] listed, and significance is compared with control group). In all experiments, the level 
of miR-204 is relative to the control RNA U6. Data are expressed as means ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001).538 miR-204 reverses pulmonary hypertension | Courboulin et al.
Altering miR-204 level promotes the activation of the pro-
proliferative and antiapoptotic Src–STAT3–NFAT pathway 
in PAH-PASMCs
The increase in PASMC proliferation and resistance to apop-
tosis observed in PAH has been linked to the activation of the 
Src–STAT3–BMPR2 (Wong et al., 2005; Brock et al., 2009) 
and NFAT pathways (Bonnet et al., 2007b). The putative im-
plication of miR-204 in these pathways was thus investigated. 
As expected, we observed an increase in the activity of Src 
(increased  phosphorylated  Src  [p-Src]/Src  ratio;  Fig.  2  B), 
STAT3 (increased p-STAT3/STAT3 ratio and p-STAT3   
nuclear translocation; Fig. 2 C and Fig. S3 A), and NFATc2 
(increased expression, nuclear translocation, and luciferase ac-
tivity; Fig. 2 D and Fig. S3 A) in PAH-PASMCs. An increase 
in miR-204 level altered the activation of Src, STAT3, and 
NFATc2 in PAH-PASMCs, whereas a decrease of miR-204 
promoted them in control PASMCs (Fig. 2 and Fig. S3). These 
findings  demonstrate  that  a  down-regulation  of  miR-204 
leads to the activation of the Src–STAT3–NFAT pathway in 
PAH-PASMCs. Activation of STAT3 was also confirmed in 
lung biopsies from PAH patients (Fig. S3 B), whereas NFATc2 
activation in PAH lungs has been previously shown by our 
group (Bonnet et al., 2007b).
Next, we attempted to identify the mechanism responsi-
ble  for  down-regulating  miR-204  in  PAH-PASMCs.  By 
stimulation experiments, we found that miR-204 expression 
is down-regulated by PDGF, endothelin-1, and angiotensin II, 
which are all well known to be involved in the pathogenesis 
of pulmonary hypertension (Zhao et al., 1996; Archer and 
Rich, 2000). Because PDGF, endothelin-1, and angiotensin II 
signaling is mainly mediated by STAT3 (Yellaturu and Rao, 
2003; Banes-Berceli et al., 2007), the effect of STAT3 inhibi-
tion by small interfering RNA (siRNA) on miR-204 was also 
investigated. We observed that siSTAT3 abolished the down-
regulation of miR-204 seen in PAH-PASMCs (Fig. 3 A). Finally, 
we found that miR-204 expression was inversely correlated 
with STAT3 activation, i.e., the higher STAT3 was activated, 
the stronger miR-204 was down-regulated (Fig. 3 B). The cod-
ing sequence of miR-204 lies within intron 6 of the human 
TRPM3 (transient receptor potential melastatin 3; Wang et al., 
2010). A previous study revealed that miR-204 and TRPM3 
share the same regulatory motif for transcription and are   
derived from a single transcription unit (Wang et al., 2010).   
This was confirmed in PAH and in control PASMCs ex-
posed to pro-PAH factors (Fig. 3 C). To further demonstrate   
the implication of STAT3 in the regulation of miR-204 ex-
pression, we performed promoter region analysis of TRPM3 
using ENCODE (encyclopedia of DNA elements) chromatin  Figure 2.  miR-204 modulates the Src–STAT3–NFATc2 pathway in 
PASMCs from a patient with PAH (PAH-PASMCs). (A) miR-204 regulates 
human PASMC apoptosis and proliferation. Analysis of PASMC proliferation 
(PCNA nuclear localization) and serum starvation–induced apoptosis (TUNEL 
staining) of PASMCs from PAH patients (n = 3 patients) and healthy controls 
(n = 5 individuals). Control (Ctrl) or miR-204 antagomirs (Inh) were added as 
indicated. (B and C) miR-204 down-regulation in PAH-PASMCs increases Src 
and STAT3 activation. Total and phosphorylated Src (B) and total and phos-
phorylated STAT3 (C) in PASMCs from three PAH and five control patients 
monitored by Western blots are shown. Control or miR-204 antagomirs or 
mimics were added when indicated. Smooth muscle actin (SM-actin) was 
used as a loading control. Representative Western blots are shown. (D) miR-
204 down-regulation in PAH-PASMCs increases NFAT expression and activa-
tion in human PASMCs. NFATc2 mRNA expression (left) and activity (right) 
were measured by qRT-PCR (left) and luciferase assay (right) in PASMCs from 
control or PAH patients treated either with control or miR-204 antagomir. 
Error bars represent mean value ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001).JEM VOL. 208, March 14, 2011 
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immunoprecipitation (ChIP) sequencing (seq; ChIP-seq) data 
for the STAT family of transcription factors and identified 
three putative STAT-binding sites located nearby the promoter 
region of TRPM3 (Fig. S3 C). We therefore tested whether 
STAT3 can bind directly to these regulatory sites. ChIP using 
p-STAT3 antibody followed by PCR brought direct support 
for a STAT3–TRPM3 interaction (Fig. 3 D). These data   
suggest  that  STAT3  may  diminish  the TRPM3/miR-204 
gene locus, leading to the activation of Src and NFAT.
In human vascular smooth muscle cells, the down-regulation 
of TRPM3 promotes IL-6 production by an undiscovered 
mechanism (Naylor et al., 2010). As TRPM3 is down-regulated 
in PAH (Fig. 3 C) and IL-6 has been reported to be in-
creased in PAH (Humbert et al., 1995), TRPM3 might be 
implicated in the etiology of PAH and thus could account for 
the PAH phenotype. Nonetheless, TRPM3 inhibition using 
siRNA in control PASMCs did not mimic the PAH pheno-
type (no changes in [Ca2+]i, DYm, and PASMC proliferation 
and apoptosis; Fig. S4). These effects were not associated with 
miR-204. Indeed, as miR-204 is localized within an intronic 
region of TRPM3, siTRPM3 did not affect miR-204 levels 
(Fig. S4). Moreover, we demonstrate that miR-204 effects are 
not mediated by TRPM3 as within 48 h, ectopic increases   
of miR-204 inhibit the Src–STAT3 axis, decreasing PAH-
PASMC proliferation, resistance to apoptosis, and IL-6 secre-
tion without restoring TRPM3 expression, whereas miR-204 
down-regulation in control PASMCs mimics PAH without 
decreasing TRPM3 (Fig. S4, A and B; Wang et al., 1999). The 
fact that miR-204 regulates IL-6 secretion (Fig. S4 B) and in-
creases Src activity (Fig. 2) in PAH-PASMCs (which had been 
linked to several pathophysiological processes seen in PAH 
such as cell proliferation [Steiner et al., 2009] and migration 
and K+ channel inhibition [Wong et al., 2005], as well as 
BMPR2 down-regulation [Wong et al., 2005]) suggests that 
miR-204 down-regulation might indirectly down-regulate 
BMPR2. We showed a significant up-regulation of BMPR2 
in both human PAH-PASMCs and in PAs from PAH rats 
treated with miR-204 mimic (Fig. S5, A and B). This could 
result from the inhibition of STAT3 by the increase in miR-
204, which would block the previously described STAT3- 
dependent  BMPR2  down-regulation 
(Brock  et  al.,  2009)  because  siSTAT3 
also increases BMPR2 expression in human 
PAH-PASMCs (Fig. S5, A and B).
Figure 3.  A primary STAT3 activation by  
circulating pro-PAH factors accounts for  
miR-204 down-regulation in PAH-PASMCs.  
(A) siSTAT3 increases miR-204 expression in PAH-
PASMCs. miR-204 level measured by qRT-PCR in 
PAH treated with control siRNA (siRNA ctrl) or 
siSTAT3 as indicated (n = 3). (B) STAT3 activation 
and miR-204 expression are inversely correlated in 
PASMCs. Analysis of the correlation between STAT3 
activation (measured by the pY705-STAT3/STAT3 
ratio monitored by Western blot) and miR-204 
expression (measured by qRT-PCR; n = 2 experi-
ments/patient in three PAH and five control pa-
tients). (C) Pro-PAH factors decrease miR-204 and 
TRPM3 expression similarly by a STAT3-dependent 
mechanism in control PASMCs. miR-204 (top) and 
TRPM3 (middle) expression were measured by qRT-
PCR performed on control cells treated with the 
pro-PAH factors PDGF, endothelin-1 (ET-1), or 
angiotensin II (AII) as indicated (n = 3 experiments/
patient/in three PAH and five controls). (bottom) 
Analysis of the similarities between miR-204 and 
TRPM3 pattern of expression measured by qRT-
PCR in control, PAH, and PAH treated with siSTAT3 
as indicated. (D) p-STAT3–binding sites are de-
tected downstream of the TRPM3 gene. ChIP-PCR 
experiments studying STAT3-binding sites up-
stream (Up1) and downstream (Dw1 and Dw2) on 
TRPM3 genes. The OR8J1 gene was used as a nega-
tive control, whereas the VEGF gene was used as  
a positive control. Graphs represent means ± SEM 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001).540 miR-204 reverses pulmonary hypertension | Courboulin et al.
Among JAK2, SHP2, and SHC, only SHP2 was up-regulated 
in PAH-PASMCs (Fig. 4 A and Fig. S5 C). Moreover, increasing 
miR-204 level in PAH-PASMCs decreased SHP2, whereas 
miR-204 inhibition in control PASMCs cells increased SHP2 
expression (Fig. 4 A). These results suggest that SHP2 may be 
the primary target of miR-204 in PAH. To test this hypothesis, 
we performed a reporter assay in which the luciferase reporter 
gene was under control of the SHP2 3 UTR. We observed that 
both point mutations that abrogate the binding site of miR-204 
in SHP2 3 UTR as well as the sequestration of miR-204 
with a specific inhibitor increase the expression of the luciferase 
reporter,  confirming  the  implication  of  miR-204  in  the 
regulation of SHP2 mediated through its 3 UTR (Fig. 4 B). 
Finally, as expected, the SHP2-dependent activation of Src 
Src activation by miR-204 promotes STAT3 and NFAT 
activation in PAH-PASMCs
From in silico analysis using TargetScan 5.1, neither STAT3 
nor NFATc1, -c2, or -c3 (three NFAT isoforms activated 
in PAH-PASMCs; Bonnet et al., 2007b) is a predicted target 
of miR-204. But because a decrease in miR-204 expression 
increases STAT3 and NFAT activation (Fig. 2, B and C), 
miR-204 may be indirectly implicated in both STAT3 and 
NFAT activation. STAT3 activation mostly results from the 
activation of either the JAK2 or Src pathways (Gharavi et al., 
2007; Cheranov et al., 2008; Li et al., 2008). Interestingly, 
among all the predicted targets of miR-204, JAK2 as well as 
two Src activators (SHP2 [Wu et al., 2006] and SHC [Src ho-
mology 2 domain containing; Sato et al., 2002]) were identified. 
Figure 4.  SHP2 up-regulation by miR-204 promotes activation of the Src–STAT3–NFAT axis in PAH-PASMCs. (A) SHP2 is up-regulated by 
miR-204 in PAH-PASMCs. Total and phosphorylated JAK2 (left), SHC1 (middle), and SHP2 (right) protein expression was monitored by Western blot (n = 3 
independent experiments) in PASMCs from three PAH and five control patients. (right) miR-204 antagomir (Inh) and mimic along with appropriate con-
trols (Ctrl) were added as indicated. SM-actin, smooth muscle actin. (B) miR-204 directly targets the SHP2 3 UTR. (left) Binding sites of miR-204 found in 
the 3 UTR of SHP2. Mutations introduced into the luciferase reporter are shown in red. (right) Relative firefly luciferase activity derived from the SHP2  
3 UTR and SHP2 3 UTR mutated reporter constructs monitored after transfection in control PASMCs (n = 5). Control and miR-204 inhibitor (n = 3) were 
added as indicated. L.U., luciferase unit. (C) STAT3 regulates NFATc2 expression. NFATc2 mRNA level (left) relative to 18S measured by qRT-PCR in PASMCs 
from control and PAH patients treated when indicated with control or STAT3 siRNA (n = 3 qRT-PCR/patient in three PAH and five control patients). ChIP-
PCR experiments (right) studying STAT3 binding on genes encoding the indicated NFAT isoforms (NFATc1, -c2, and -c3). The OR8J1 gene was used as a 
negative control, whereas the VEGF gene was used as a positive control. Graphs represent means ± SEM (*, P < 0.05; **, P < 0.01).JEM VOL. 208, March 14, 2011 
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the miR-204 level in PAH-PASMCs inhibits cell proliferation 
(PCNA; Fig. 5 C). In addition to the STAT3–NFAT axis, the 
antiproliferative and proapoptotic effect of SHP2 inhibition by 
siRNA or miR-204 mimic could also be attributed to the 
inhibition of the RhoA–ROCK (Rho-associated, coiled-coil–
containing protein kinase) pathway (Fig. S6 D; Lee and Chang, 
2008; Kimura and Eguchi, 2009), which is increased and impli-
cated in PAH-PASMC proliferation (Barman et al., 2009).
Based on the fact that miR-204 is encoded within TRPM3 
(Wang et al., 2010) and TRPM3 expression modulation may 
account for changes in [Ca2+]i, we tested whether miR-204–
dependent modulation of [Ca2+]i could be attributed to 
TRPM3. We demonstrated that restoring miR-204 consti-
tutes the primary therapeutic target, as TRPM3 inhibition by 
siRNA (which did not affect miR-204 expression as miR-
204 is located within an intronic region) did not affect [Ca2+]i 
and PASMC proliferation (Fig. S4).
Resistance to apoptosis observed in PAH-PASMCs has 
been linked to mitochondrial membrane potential (m) hy-
perpolarization, which would block the release of proapop-
totic mediators like cytochrome c (Bonnet et al., 2007a, b, 
2009). Using tetramethylrhodamine methyl ester (TMRM), 
we measured whether miR-204 modulation can affect mito-
chondrial hyperpolarization. We observed that miR-204 in-
hibition in control PASMCs hyperpolarizes m to a level 
similar to that observed in PAH-PASMCs (Fig. 5 D), whereas 
either increasing the miR-204 level or using SHP2 siRNA, 
Src inhibitor PP2, or STAT3 siRNA in PAH-PASMCs de-
polarizes m to a level similar to that measured in control 
PASMCs (Fig. 5 E). Finally, mitochondrial depolarization in-
duced by up-regulating miR-204 expression in PAH-PASMCs 
increases serum starvation–induced apoptosis (terminal de-
oxynucleotidyl transferase dUTP nick end labeling [TUNEL]; 
Fig. 5 F). As for [Ca2+]i, m was not affected by TRPM3   
inhibition (Fig. S4).
The STAT3–miR-204–Src–STAT3–NFAT axis is activated  
in the PAH animal model
We next tested the contribution of miR-204 in the MCT- 
injected rat model of PAH (Frasch et al., 1999; Bonnet et al., 
2007b). We observed that miR-204 down-regulation paral-
lels PAH development, confirming that the decreasing of 
miR-204 level correlates with PAH progression and severity 
(Fig. 6, A and E). To further study the timing of activation of 
the STAT3–miR-204–Src–STAT3–NFAT axis in the pro-
gression of PAH, rats were sacrificed at various intervals   
after the injection of MCT. Before sacrifice, pulmonary arterial 
pressure was measured directly by right heart catheterization in 
closed chest rats. We observed an increase in STAT3 activa-
tion (≤1 wk; Fig. 6 C) preceding miR-204 down-regulation 
(occurring 2 wk after MCT injection). Once miR-204 is 
down-regulated (≥2 wk), SHP2 is increased and STAT3 ac-
tivation is pushed up to reach and sustain a maximal level 
from week 2–4 (Fig. 6, B and C). Once STAT3 activation 
becomes maximal, NFAT gets activated (≥3 wk; Fig. 6 D), in-
creasing pulmonary arterial pressure (Fig. 6 E). Therefore, the 
accounts for an increase in STAT3 activation in PAH-PASMCs 
as either SHP2 knockdown by siRNA or the Src inhibitor 
PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-
d]pyrimidine) significantly decreases STAT3 activation in PAH-
PASMCs (Fig. S6 A). Thus, the attenuation of miR-204 level 
promotes SHP2 expression, thereby leading to Src activation 
and thus enhancing STAT3 activation.
NFAT activation mainly results from the activation of   
either calcineurin (Macian, 2005) or Pim-1 (Glazova et al., 
2005), but none of them are predicted targets of miR-204. 
This was confirmed by luciferase assay (Fig. S6 B). The ChIP-
seq data revealed the presence of several STAT-binding sites 
surrounding NFAT genes (Fig. S6 C; Chen et al., 2008; 
Bourillot et al., 2009). Thus, we inferred that SHP2–Src acti-
vation results in STAT3 activation, which in turn activates 
NFAT in PAH-PASMCs. To demonstrate the implication of 
STAT3 in the regulation of NFATc2 expression in PAH, the 
effect  of  STAT3  knockdown  on  NFATc2  expression  was 
measured  in  PAH-PASMCs  and  control  PASMCs. When 
compared with PAH-PASMCs treated with control siRNA, 
PAH-PASMCs exposed to siRNA targeting STAT3 exhib-
ited significantly reduced NFATc2 expression (Fig. 4 C), sug-
gesting that STAT3 activation leads to NFATc2 expression in 
PAH-PASMCs. Moreover, ChIP analyzed by real-time PCR 
(ChIP-PCR)  confirmed  the  binding  of  STAT3  on  the 
NFATc2 gene (Fig. 4 C). NFAT activation by SHP2–Src has 
been described in skeletal muscle (Fornaro et al., 2006), and 
our findings not only confirm this previous finding but pro-
vide an additional mechanism implying STAT3.
Increasing miR-204 level in PAH-PASMCs reverses the  
pro-proliferation and antiapoptotic phenotype of PAH-PASMCs
In PAH-PASMCs, Src–STAT3–NFAT-mediated proliferation 
(Wong et al., 2005; Bonnet et al., 2007b) has been linked to 
the down-regulation of K+ channels (Platoshyn et al., 2000; 
Bonnet and Archer, 2007), resulting in membrane depolariza-
tion (Yuan, 1995; Platoshyn et al., 2000), opening the voltage-
dependent Ca channels, thereby increasing intracellular Ca 
concentration ([Ca2+]i; Yuan, 1995; Wong et al., 2005; Bonnet 
et al., 2007b). Using Fluo-3AM and proliferating cell nuclear 
antigen (PCNA), we measured the effect of miR-204 modu-
lation on [Ca2+]i and PASMC proliferation. The miR-204 in-
hibition in control PASMCs increases [Ca2+]i and PASMC 
proliferation to the level seen in PAH-PASMCs, whereas the 
increase of miR-204 level in PAH-PASMCs decreases [Ca2+]i 
and proliferation to a level similar to that seen in control 
PASMCs (Fig. 5, A and C). To further confirm that these   
effects were mediated via the Src–STAT3 and NFAT pathway, 
we treated cells with the Src inhibitor PP2, STAT3 siRNA, 
and the NFAT inhibitor VIVIT (Bonnet et al., 2007b). As   
expected, VIVIT treatment does not further decrease [Ca2+]i 
in PAH-PASMCs in which the miR-204 level has been re-
established (Fig. 5, A and C), whereas in PAH-PASMCs, PP2 
and siSTAT3 decrease [Ca2+]i to a level similar to that seen in 
control PASMCs (Fig. 5 B). Similarly to SHP2 inhibition 
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lowing NFAT-dependent PASMC proliferation and resistance 
to apoptosis and increasing PA remodeling and pressures.
Nebulization of miR-204 mimics reverses MCT-induced PAH
To  test  whether  restoration  of  miR-204  level  can  reverse 
symptoms of PAH in the rat model, synthetic miR-204   
RNA  molecules  were  selectively  delivered  to  the  lung  of 
time course analysis confirms our in vitro data supporting 
the idea that the activation of STAT3 occurs before the de-
crease in miR-204, which thereby amplifies the activation of 
STAT3 and NFAT. These results confirmed the initial im-
plication of STAT3 in the attenuation of miR-204 in PAH. 
Once miR-204 is down-regulated, STAT3 activation is further 
increased and maintained over a long period of time, thus al-
Figure 5.  miR-204 restoration decreases [Ca2+]i and depolarizes mitochondrial membrane potential. (A–C) Analysis of [Ca2+]i (Fluo3-AM) and 
cell proliferation (PCNA nuclear localization) of PASMCs from PAH and control (Ctrl) patients. miR-204 antagomir (Inh) and mimics, VIVIT (NFAT competi-
tor peptide), and PP2 (Src inhibitor) compared with PP3, its negative control, STAT3 siRNA, SHP2 siRNA, and appropriate controls for each treatment were 
added as indicated (n = 50–150 cells/patient in three PAH and five control patients). (D–F) Analysis of the mitochondrial membrane potential (m; 
TMRM) and serum starvation–induced apoptosis (TUNEL staining) of PASMCs from PAH and control patients. miR-204 antagomir (Inh) and mimics, VIVIT 
(NFAT competitor peptide), PP2 (Src inhibitor), STAT3 siRNA, SHP2 siRNA, and appropriate controls for each treatment were added as indicated (n = 50–
150 cells/patient in three PAH and five control patients). F.U., fluorescence unit. Graphs represent means ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
Figure 6.  miR-204 level decreases within distal PAs of rats injected with MCT during the fourth week of PAH development. (A) miR-204  
expression relative to U6 measured by qRT-PCR in distal PAs of rats. (B) SHP2 protein expression was quantified in distal PAs by immunofluorescence  
(F.U., fluorescent unit) on lung sections (n = 5 measurements by rat in five rats per time point). (C and D) STAT3 and NFAT activation were measured by the per-
centage of cells presenting p-STAT3 and NFAT nuclear localization, respectively, in distal PAs of rats (n = 5 measurements by rat in 10 rats per time point). (E) Mean 
PA pressure measured by right catheterization in closed chest rats (n = 5 rats per group). Graphs represent means ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001).JEM VOL. 208, March 14, 2011 
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MCT-PAH rats treated with nonspecific synthetic RNA mol-
ecules. In an opposite manner, miR-204 antagomir nebuliza-
tion in control rats induced PAH development within 3 wk 
(Fig. 7 A and Fig. S7 B), whereas antagomir negative control 
nebulized to two animals had no effects (not depicted). To de-
termine whether synthetic miR-204 delivery can reduce PA 
remodeling in MCT-PAH animals, we measured medial wall 
thickness. We observed that animals treated with the synthetic 
miR-204 displayed a significant reduction in medial thickness 
of small (≤300 µm) and medium-sized (≤600 µm) PAs (Fig. 7 
B). A significant decrease of SHP2, p-STAT3, NFATc2 activa-
tion, PASMC proliferation (as assessed by PCNA distribu-
tion), and resistance to apoptosis (TUNEL) was also observed 
in rats treated with synthetic miR-204 (Fig. 7 C and Fig. S8).
DISCUSSION
Although a previous study has reported that several miRNAs 
were aberrantly expressed in PAH (Caruso et al., 2010), our 
study is the first providing a mechanistic approach to their 
MCT-induced PAH (MCT-PAH) rats 10–15 d after MCT in-
jection (when endogenous miR-204 down-regulation reached 
its peak and PAH was established) by intratracheal nebuliza-
tion. To verify the tissue distribution of nebulized miR-204, 
we  measured  miR-204  mRNA  levels  in  several  tissues  by 
qRT-PCR, and we analyzed by immunofluorescence the dis-
tribution of the mimic DY547 labeled (control of transfection; 
Fig. S7 A). Our results revealed that nebulized synthetic miR-
204 is essentially localized to intraparenchymal resistance PAs 
and therefore has limited, if any, detrimental effect.
A longitudinal study to assess the efficacy of our treatment 
was  performed  for  2  wk  using  noninvasive  measurements 
(Doppler  echocardiography). We  observed  that  the  local   
delivery of synthetic miR-204 in MCT-PAH rats reduced 
pulmonary arterial pressure (Fig. 7 A), as assessed by the PA 
acceleration time (PAAT), a Doppler parameter linked to PA 
pressure  (PAAT  being  inversely  correlated  to  PA  pressure;   
Fig. S7 B). In addition, synthetic miR-204 decreased right 
ventricle  wall  thickness  (Fig.  S7  B)  when  compared  with 
Figure 7.  Increasing the level of miR-204 by nebulization reverses MCT-PAH. (A) miR-204 restoration decreases mean PA pressure. Mean PA 
pressure measured by right catheterization in closed chest rats (n = 5 rats per group) is shown. miR-204 antagomir (Inh) and mimic along with appropri-
ate controls (Ctrl) as indicated were intratracheally nebulized after 2 wk of MCT injection. (B) miR-204 restoration decreases PA wall thickness. PA remod-
eling was measured by the percentage of media wall thickness on lung sections stained by hematoxylin and eosin (n = 5 measurements/rat in 10 rats). 
The pictures shown illustrate representative distal arteries, and the graph represents mean values. (C) By decreasing SHP2, STAT3, and NFAT activation, 
miR-204 restoration increases apoptosis and decreases proliferation in MCT-rat PASMCs. SHP2 protein expression (left) was quantified in distal PAs by 
immunofluorescence (F.U., fluorescent unit) on lung sections; STAT3 and NFAT activation (middle) measured by the percentage of cells presenting p-STAT3 
and NFAT nuclear localization, respectively, in distal PAs of rats; apoptosis and proliferation measured by the percentage of cells presenting TUNEL and 
PCNA nuclear localization, respectively, in distal PAs of rats. Control and miR-204 mimic were intratracheally nebulized after 2 wk of MCT injection as 
indicated (n = 5 measurements by rat in five rats per group). Graphs represent means ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001).544 miR-204 reverses pulmonary hypertension | Courboulin et al.
cluster expression and down-regulating BMPR2. Despite the 
fact that miR-17-92 cluster expression is unchanged in 
our PAH-PASMCs, our study offers a new perspective on 
the mechanism of BMPR2 down-regulation in PAH. The 
fact that miR-204 regulates IL-6 secretion (Fig. S4 B) and   
increases Src activity (Fig. 2) in PAH-PASMCs suggests that 
miR-204 down-regulation might indirectly down-regulate 
BMPR2. This is supported by preliminary data showing a 
significant up-regulation of BMPR2 in both human PAH-
PASMCs and in PAs from PAH rats treated with miR-204 
mimic (Fig. S5).
One major strength of the present study is the clear dem-
onstration of a mechanism for the origin of the miRNA de-
regulation in 10 PAH patients that we provide for the first 
time in the field of vascular diseases. We show that a primary 
STAT3 activation by circulating pro-PAH factors such as   
endothelin-1, PDGF, and angiotensin II (which all increase at 
the onset of PAH; Archer and Rich, 2000) accounts for the 
down-regulation of miR-204 in control PASMCs. This find-
ing was confirmed by both promoter analysis and ChIP-PCR 
analysis, which show a direct binding of STAT3 near the 
miR-204 gene (within TRPM3; Fig. 3 D). Moreover, we 
showed that the activation of STAT3 in vivo in PAs of rats   
injected with MCT precedes miR-204 down-regulation   
(Fig. 6 C). Once miR-204 is down-regulated, the Src activa-
tor SHP2 is directly up-regulated and IL-6 (Fig. S4 B) and 
PDGF production (Wang et al., 2010) increased, reinforcing 
STAT3 activation via Src and allowing NFAT activation. This 
could explain the sustained pro-proliferative and antiapop-
totic phenotype of cultured PAH-PASMCs. The activation of 
such a mechanism is in accordance with a recently published 
RNA profiling study performed in 18 iPAH patients (Rajkumar 
et al., 2010). A reanalysis of the data available for this study 
confirms the down-regulation of TRPM3 as well as the   
up-regulation of both SHP2 (also known as PTPN11) and 
NFATc2. Although  we  provide  evidence  that  STAT3  in-
creases NFAT expression by binding to the NFAT genes pro-
moter region, the activation of NFAT by STAT3 requires the 
activation of either the Ca–calcineurin pathway or the activa-
tion  of  other  NFAT  activators  like  Pim-1.  In  our  model, 
[Ca2+]i is indeed increased, which could participate in calci-
neurin activation. Moreover, Pim-1 is a protooncogene that is 
regulated by STAT3 and that increases in vascular diseases 
(Katakami et al., 2004). It is therefore possible that STAT3 ac-
tivation not only accounts for NFAT expression but also pro-
motes NFAT activation by up-regulating Pim-1 expression 
(Rainio et al., 2002). Finally, we measured miR-204 expression 
in buffy coats of 13 PAH patients and 7 control donors and 
showed that as in PAH lungs, miR-204 is down-regulated, 
suggesting that miR-204 could be a good PAH biomarker.
In conclusion, we herein provide the first evidence that 
aberrantly expressed miRNAs play a critical role in the etiol-
ogy of human PAH. We demonstrate both in vitro and in vivo 
that miR-204 can be therapeutically targeted, leading to a 
decrease of proliferation, vascular remodeling, and PA blood 
pressure and thus represents a new therapeutic approach for 
implication in the etiology of human PAH. Despite the fact 
that several other miRNAs are aberrantly expressed in PAH-
PASMCs, we focused our study on miR-204, which was the 
only one down-regulated, and because putative mRNA targets 
predicted in silico (TargetScan 5.1) were members of path-
ways implicated in cell proliferation and resistance to apopto-
sis, including Src (Wong et al., 2005), STAT3 (Shibata et al., 
2003),  and  NFAT  (Fig.  S1;  Bonnet  et  al.,  2009).  Because   
miR-204 is expressed seven times more in PASMCs than 
PAECs, we focused our research on the role of miR-204   
in  PAH-PASMC  proliferation  and  resistance  to  apoptosis,   
although we cannot exclude a role of miR-204 in PAH-
PAECs, which are also implicated in PAH etiology (Jurasz   
et al., 2010).
Other miRNAs have been implicated in vascular diseases, 
but their implication remains elusive. For example, although a 
recent study has shown that miR-21 up-regulation was impli-
cated in vascular neointimal lesions (Ji et al., 2007), miR-21 has 
been shown to be down-regulated in lung tissue of MCT rats 
and unchanged in chronic hypoxia (Caruso et al., 2010). Inter-
estingly, in our human PAH-PASMCs, miR-21 is unchanged, 
suggesting that miR-21 might not necessarily be an impor-
tant player in the etiology of PAH. Interestingly, in the Caruso 
et al. (2010) study, miR-204 is down-regulated by 45% and 
40% in both chronic hypoxic and MCT rat lungs, respectively, 
confirming our findings in PASMCs and human lungs.
The role of miR-204 in vascular tissues remained unknown. 
A recent study performed in retinal epithelial cells and several 
cancer cells has demonstrated that the down-regulation of   
miR-204 is associated with enhanced PDGFb expression, cell 
proliferation, and the down-regulation of K+ channels, which 
in turn depolarizes epithelial cell membrane potential (Wang   
et al., 2010). These findings are consistent with ours and with 
the already known pathophysiological processes of PAH, re-
inforcing the importance of miR-204 in the etiology of PAH. 
Indeed, increased PDGFb has been reported in PAH (Barst, 
2005), and this is consistent with STAT3 activation (PDGFb 
being an activator of STAT3; Yu et al., 2003), PASMC prolifera-
tion, and resistance to apoptosis (Bonnet et al., 2009).
miR-204  is  encoded  within  the  TRPM3  gene. Al-
though, transient receptor potential cation channels have 
been implicated in PAH (Yu et al., 2004), the role of TRPM3 
remains unknown. In our study, we demonstrate that miR-
204 effects are not mediated by TRPM3. First, ectopic in-
creases  of  miR-204  inhibit  the  SHP2–Src–STAT3  axis, 
decreasing PAH-PASMC proliferation, resistance to apopto-
sis, and IL-6 secretion without restoring TRPM3 expression 
(Fig.  S4, A  and  B).  Second,  miR-204  down-regulation  in 
control PASMCs mimics PAH, without decreasing TRPM3 
(Fig.  S4 A). Third, TRPM3  inhibition  (without  affecting 
miR-204 levels) did not induce a PAH phenotype in control 
PASMCs (Fig. S4 C).
Recently, a study performed in human PASMCs linked 
the down-regulation of BMPR2 to the activation of an IL-6–
STAT3–miR-17-92 axis (Brock et al., 2009). In their model, 
IL-6  activates  STAT3,  thereby  increasing  the  miR-17-92 JEM VOL. 208, March 14, 2011 
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10 nM endothelin-1, 200 nM angiotensin II, or 100 ng/ml TNF (all from 
EMB Canada). The Src inhibitor PP2 effects were compared with its negative 
control inhibitor PP3 (4-amino-7-phenylpyrazol [3,4-d] pyrimidine; 10 µM for 
48 h). The Ca phosphate transfection method was used to transfect miRIDAN 
miR-204 mimics (200 nM for 48 h) or miR-204 antagomir (hairpin inhibi-
tor at 200 nM for 48 h). For each experiment, we used a proper control 
(mimics or hairpin inhibitor negative control #1 from Thermo Fisher Scien-
tific). Dose response, transfection efficiency, and siRNA efficiencies are pre-
sented in Fig. S8 C.
TaqMan low density arrays (TLDAs). TLDA was performed in four   
patients, two for each condition, and according to the manufacturer’s pro-
tocol (Applied Biosystems). Each sample was analyzed in duplicate. Raw 
CTs were then normalized using two different normalization procedures, 
one normalizing relative to U6 small nuclear RNA and the other one relative 
to the median CT. An empirical Bayesian method within the package 
limma in Bioconductor was used to identify the significantly modulated 
miRNAs. miRNAs were required to be significantly modulated for both 
normalizations. TLDA data have been deposited in GEO DataSets under ac-
cession no. GSE21284.
DNA microarrays. DNA microarray experiments were performed using 
the Whole Human Genome microarray kit (Agilent Technologies). The ar-
rays were scanned using a dual-laser DNA microarray scanner (Agilent Tech-
nologies),  and  the  data  were  extracted  from  images  using  the  Feature 
Extraction software. For the control versus PAH patient comparison, RNAs 
extracted from two control patients were hybridized on Cy3, and RNAs ex-
tracted from two PAH patients were hybridized on Cy5. For the miR-204 
inhibition experiment, RNAs extracted from control PASMCs treated for   
48 h with 200 nM miR-204 antagomir (Thermo Fisher Scientific) were hybrid-
ized with Cy3, whereas PASMCs treated with antagomir negative were hybrid-
ized on Cy5. Data were background subtracted and normalized within the array 
using the LOESS normalization before significant modulation assessment 
using the Empirical Bayes method within limma in Bioconductor. Genes 
listed as targets of miR-204 in TargetScan 5.1 and having a level of expression 
≥100 in log2 base and being up-regulated after miR-204 inhibition were 
considered as miR-204 targets in our model. Microarray data have been de-
posited in GEO DataSets and are available under accession no. GSE21284.
qRT-PCR. To measure miR-204 expression, the mirVana kit (Applied Bio-
systems) was used to extract total RNA from PAH-PASMCs or control 
PASMCs. Stem-loop qRT-PCR for mature miRNAs was performed on a 
real-time PCR system (AB 7900; Applied Biosystems). Regular qRT-PCR 
was performed as previously described (Bonnet et al., 2007b).
ChIP-PCR. In brief, control PASMC asynchronously growing cells were 
treated with endothelin at 10 nM. Cross-links were generated with 1% form-
aldehyde, and chromatin was extracted in lysis buffer (50 mM Tris-HCl,   
pH 8, 10 mM EDTA, 0.2% SDS, and 5 mM Na-butyrate). Chromatin was 
then sheared by sonication (Bioruptor; Diagenode) on ice to a mean length 
of 750 bp. After preclearing with a mix of protein A/G–Sepharose beads (4°C 
for 1 h), 80 µg chromatin was used for immunoprecipitation with appropriate 
antibodies (10 ml p-Sat3 [Tyr705; 9131; Cell Signaling Technology] and   
10 mg normal rabbit IgG [I-1000; Vector Laboratories]) in a total volume of 
300 ml. After overnight incubation at 4°C, 25 µl of protein A Dynabeads   
(Invitrogen)  was  added  and  incubated  for  >1  h.  Beads  were  extensively 
washed, and immunoprecipitated complexes were eluted in buffer E (50 mM 
Na bicarbonate and 1% SDS). Cross-links were reversed overnight at 65°C. 
Samples were treated with proteinase K, and the DNA was extracted using 
phenol-chloroform.  Quantitative  real-time  PCR  was  performed  using 
SYBR green I (LightCycler 480; Roche). Enrichment for a specific DNA 
sequence was calculated using the comparative Ct method. The numbers 
presented with standard errors are based on two biological repeats (cells/
chromatin/immunoprecipitation). Primers used in the PCR reactions (Table S2) 
were analyzed for specificity, linearity range, and efficiency to accurately 
PAH. Moreover, we have preliminary evidence that miR-204 
might regulate the RhoA–ROCK pathway in PAH-PASMCs 
(another important component of PAH; Fig. S6 D; Doggrell, 
2005). Although other experiments are required to identify 
the exact mechanism, Bregeon et al. [2009] and Kimura and 
Eguchi [2009] have previously demonstrated a role of SHP2 
in the RhoA–ROCK pathway. This constitutes the basis for a 
further investigation. Our study proposes that the therapeutic 
modulation of a single miRNA (miR-204) may affect many 
pathways simultaneously associated with PAH to achieve 
clinical benefit. Compared with currently used therapies that 
target a single protein (ET-1 receptor blockers, PDE5 inhibi-
tor, etc.), the regulation of hundreds of targets in multiple 
pathways by miRNAs may reduce the emergence of drug re-
sistant as currently seen in PAH because many simultaneous 
mutations would be required to subvert the effects of miRNA 
expression. However, at the same time, miRNA-based thera-
pies will require thorough preclinical validation as these broad 
effects may, in some cases, have toxic consequences. Nonethe-
less, this was not observed in our rats.
In summary, we provide a comprehensive model (Fig. S8 E) 
linking miRNA abnormal expression to already known patho-
physiological processes in PAH, including NFAT activation, 
BMPR2 down-regulation, IL-6 production, the Rho pathway, 
PASMC proliferation, and resistance to apoptosis (Cowan   
et al., 2000; Sakao et al., 2005; Bonnet and Archer, 2007; 
Bonnet et al., 2007b; Tuder et al., 2007). Thus, our study does 
not only demonstrate the importance of miRNAs in PAH 
but also suggests that reestablishing the miR-204 level might 
represent a novel therapeutic approach for human PAH.
MATERIALS AND METHODS
Ethics. All experiments were performed in accordance with the Université 
Laval’s Ethics and Biosafety Committee (protocol number 20142) and the 
Centre Hospitalier Universitaire de Québec’s Ethics Committee. The inves-
tigation conforms to the Guide for the Care and Use of Laboratory Animals, 
published by the National Institutes of Health (publication no. 85–23, revised 
1996) and with the principles outlined in the Declaration of Helsinki.
Human tissue samples. See Table S1. All patients gave informed consent 
before the study. Normal lung tissues (controls) were obtained during lung 
resection for benign (n = 3) or malignant (n = 5) tumors. Only the healthy 
parts of the lungs were used in this study. All the PAH tissues were from open 
lung explants from transplant or autopsy.
Cell culture. We used cells in the first to third passage. PAH-PASMCs were 
obtained as described previously (McMurtry et al., 2005) from 1,500-µm-
diameter small PAs from two males with iPAH (31- and 48-yr-old patients A 
and B) and one female with PAH group 1 (lupus; 54-yr-old patient C) from 
lung explants. All patients had right catheterization that confirmed pulmo-
nary hypertension (mean pulmonary arterial pressure >25 mmHg). Age- and 
sex-matched control PASMCs (three males A, B, and C 45, 21, and 64 yr old; 
and two females D and E 17 and 35 yr old), and PAECs were purchased from 
Cell Application USA. PASMCs were grown in high-glucose DME supple-
mented with 10% FBS (Invitrogen) and 1% antibiotic/antimitotic (Invitro-
gen; Bonnet et al., 2007a). STAT3 and SHP2 were inhibited by a specific 
siRNA (20 nM for 48 h; Applied Biosystems) as previously described (Bonnet   
et al., 2007a). NFAT was inhibited by 4 µM VIVIT as previously described 
(Bonnet et al., 2007b). Control PASMCs were exposed to 30 ng/ml PDGF, 546 miR-204 reverses pulmonary hypertension | Courboulin et al.
lists primers used for ChIP–real-time PCR. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20101812/DC1.
This work has been funded by grants from the Canadian Institutes of Health 
Research (CIHR) to S. Bonnet, M.J. Simard, and J. Côté (MOP-64289). M.J. Simard is 
a CIHR New Investigator. S. Bonnet and J. Côté hold Canada Research Chairs.
The authors have no conflicting financial interests.
Submitted: 31 August 2010
Accepted: 19 January 2011
REFERENCES
Archer, S., and S. Rich. 2000. Primary pulmonary hypertension: a vascu-
lar biology and translational research “Work in progress”. Circulation. 
102:2781–2791.
Banes-Berceli, A.K., P. Ketsawatsomkron, S. Ogbi, B. Patel, D.M. Pollock, and 
M.B. Marrero. 2007. Angiotensin II and endothelin-1 augment the vas-
cular complications of diabetes via JAK2 activation. Am. J. Physiol. Heart 
Circ. Physiol. 293:H1291–H1299. doi:10.1152/ajpheart.00181.2007
Barman, S.A., S. Zhu, and R.E. White. 2009. RhoA/Rho-kinase signaling: a 
therapeutic target in pulmonary hypertension. Vasc. Health Risk Manag. 
5:663–671. doi:10.2147/VHRM.S4711
Barst, R.J. 2005. PDGF signaling in pulmonary arterial hypertension. J. Clin. 
Invest. 115:2691–2694. doi:10.1172/JCI26593
Bonnet, S., and S.L. Archer. 2007. Potassium channel diversity in the pul-
monary arteries and pulmonary veins: implications for regulation of the 
pulmonary vasculature in health and during pulmonary hypertension. 
Pharmacol. Ther. 115:56–69. doi:10.1016/j.pharmthera.2007.03.014
Bonnet, S., E.D. Michelakis, C.J. Porter, M.A. Andrade-Navarro, B. Thébaud, 
S. Bonnet, A. Haromy, G. Harry, R. Moudgil, M.S. McMurtry, et al. 
2006.  An  abnormal  mitochondrial-hypoxia  inducible  factor-1alpha-
Kv channel pathway disrupts oxygen sensing and triggers pulmonary 
arterial hypertension in fawn hooded rats: similarities to human pul-
monary arterial hypertension. Circulation. 113:2630–2641. doi:10.1161/ 
CIRCULATIONAHA.105.609008
Bonnet,  S.,  S.L. Archer,  J. Allalunis-Turner, A.  Haromy,  C.  Beaulieu,  R. 
Thompson, C.T. Lee, G.D. Lopaschuk, L. Puttagunta, S. Bonnet, et al. 
2007a. A mitochondria-K+ channel axis is suppressed in cancer and its 
normalization promotes apoptosis and inhibits cancer growth. Cancer 
Cell. 11:37–51. doi:10.1016/j.ccr.2006.10.020
Bonnet, S., G. Rochefort, G. Sutendra, S.L. Archer, A. Haromy, L. Webster, K. 
Hashimoto, S.N. Bonnet, and E.D. Michelakis. 2007b. The nuclear factor 
of activated T cells in pulmonary arterial hypertension can be thera-
peutically targeted. Proc. Natl. Acad. Sci. USA. 104:11418–11423. doi:10 
.1073/pnas.0610467104
Bonnet,  S.,  R.  Paulin,  G.  Sutendra,  P.  Dromparis,  M.  Roy,  K.O. Watson, 
J.  Nagendran,  A.  Haromy,  J.R.  Dyck,  and  E.D.  Michelakis.  2009. 
Dehydroepiandrosterone reverses systemic vascular remodeling through 
the inhibition of the Akt/GSK3-beta/NFAT axis. Circulation. 120:1231–
1240. doi:10.1161/CIRCULATIONAHA.109.848911
Bourillot, P.Y., I. Aksoy, V. Schreiber, F. Wianny, H. Schulz, O. Hummel, N. 
Hubner, and P. Savatier. 2009. Novel STAT3 target genes exert distinct 
roles in the inhibition of mesoderm and endoderm differentiation in 
cooperation  with  Nanog.  Stem  Cells.  27:1760–1771.  doi:10.1002/ 
stem.110
Bregeon,  J.,  G.  Loirand,  P.  Pacaud,  and  M.  Rolli-Derkinderen.  2009.   
Angiotensin II induces RhoA activation through SHP2-dependent de-
phosphorylation  of  the  RhoGAP  p190A  in  vascular  smooth  muscle 
cells.  Am.  J.  Physiol.  Cell  Physiol.  297:C1062–C1070.  doi:10.1152/ 
ajpcell.00174.2009
Brock, M., M. Trenkmann, R.E. Gay, B.A. Michel, S. Gay, M. Fischler, S. 
Ulrich, R. Speich, and L.C. Huber. 2009. Interleukin-6 modulates the 
expression of the bone morphogenic protein receptor type II through 
a novel STAT3-microRNA cluster 17/92 pathway. Circ. Res. 104:1184–
1191. doi:10.1161/CIRCRESAHA.109.197491
Caruso, P., M.R. MacLean, R. Khanin, J. McClure, E. Soon, M. Southgate, 
R.A. MacDonald, J.A. Greig, K.E. Robertson, R. Masson, et al. 2010. 
Dynamic changes in lung microRNA profiles during the development 
of pulmonary hypertension due to chronic hypoxia and monocrotaline.  
evaluate occupancy (percentage of immunoprecipitation/input). Vascular en-
dothelial  growth  factor  (VEGF)  primers  were  used  as  positive  control, 
whereas OR8J1 primers were used as negative control.
Confocal microscopy. NFATc1 and -c2 and STAT3 nuclear translocation 
assays were performed using antibodies (1:250; Abcam) as previously de-
scribed (Bonnet et al., 2007b). TMRM, TUNEL, PCNA, and Fluo-3 were 
measured as previously described (Bonnet et al., 2009; Bonnet et al., 2007b).
Transfection and luciferase assay for different 3 UTR constructions. 
The 3 UTRs of each gene of interest were cloned and inserted in the psi-
CHECK2 plasmid immediately downstream from the stop codon of firefly 
luciferase. Once ready, cells were transfected with the reporter plasmid with 
200 nM of unrelated small RNA duplex (mimic control; Invitrogen), miR-
204 mimic (Thermo Fisher Scientific), miR-204 inhibitor (Thermo Fisher 
Scientific), or with Caenorhabditis elegans miR-67 inhibitor used as control 
(Thermo Fisher Scientific). Firefly and Renilla luciferase activities were mea-
sured consecutively using a dual-luciferase assay 48 h after transfection. The 
presence of an interaction between miR-204 and target mRNA would re-
duce the firefly luciferase activity (normalized to Renilla luciferase activity 
expressed from the psiCHECK2 plasmid). To abrogate miR-204 binding to 
the SHP2 3 UTR, point mutations were made into the 3 UTR sequence 
that corresponds to the miR-204 binding site in position 2, 4, and 6 from the 
5 end of miR-204, as illustrated in Fig. 4 B.
In vivo model rats. Male rats were injected s.c. with a 60-mg/kg MCT so-
lution (Todorovich-Hunter et al., 1988). PAH was assessed by hemodynamic 
measurements (using Swan-Gan catheters) and echocardiography (using  Vevo 
2100; VisualSonics), which were performed as previously described (Bonnet 
et al., 2007b). In vivo, rats with established PAH (measured by Echo-Doppler) 
were nebulized with miR-204 mimic (mature sequence, 3-UUCCCUUU-
GUCAUCCUAUGCCU-5) or mimic negative (20 µM once a week for   
2 wk). Invivofectamine (Invitrogen) was used as transfected agent according 
to the manufacturer’s instructions. Transfection efficiency and tissue distribu-
tion were assessed by qRT-PCR. Tissue distribution was assessed using fluo-
rescent  distribution  of  the  commercially  available  DY547-labeled  mimic 
control (Thermo Fisher Scientific).
Chronic hypoxic mice model. Mice were placed for 2–3 wk in normo-
baric hypoxic chambers maintained with 5.5–liter min1 flow of hypoxic air 
(10% O2 and 90% N2). Chambers were opened twice a week for cleaning 
and replenishment of food and water. Oxygen concentration was continu-
ously monitored with blood gas analyzers. Soda lime was used to lower car-
bon dioxide concentration.
Statistical analysis. Values are expressed as fold change or mean ± SEM. Un-
paired Student’s t tests were used for comparisons between two means. For com-
parisons between more than two means, we used one-way analysis of variance 
followed by a Dunn’s test. A p-value <0.05 was considered statistically significant 
(and indicated with asterisks). TLDA and microarray data were analyzed within 
R (http://www.r-project.org) using the limma package in Bioconductor.
Online supplemental material. Fig. S1 shows seven miRNAs that are ab-
errantly expressed in human PAH-PASMCs compared with control PASMCs. 
Fig. S2 represents the measurements of miR-204 level in the pulmonary 
vasculature and buffy coat. Fig. S3 shows that miR-204 down-regulation in 
PAH-PASMCs promotes the activation of STAT3 and NFAT. Fig. S4 shows 
that the miR-204 effect is independent of TRPM3 expression. Fig. S5 shows 
that the miR-204 mimic molecule restores BMPR2 expression in PAH. 
Fig. S6 shows that a decrease of miR-204 level activates the Src–STAT3 axis 
and promotes NFAT expression. Fig. S7 shows that miR-204 mimic intratra-
cheal nebulization restores miR-204 expression in distal PAs, which improves 
the PAAT and decreases right ventricle hypertrophy in the MCT rat model. 
Fig. S8 shows the validation of miR-204 mimic/antagomir transfection and 
siRNA effects on PASMCs. Table S1 lists patients providing tissue. Table S2 JEM VOL. 208, March 14, 2011 
Article
547
of  pim-1  in  smooth  muscle  cell  proliferation.  J.  Biol.  Chem.  279: 
54742–54749. doi:10.1074/jbc.M409140200
Khan, A.A., D. Betel, M.L. Miller, C. Sander, C.S. Leslie, and D.S. Marks. 2009. 
Transfection of small RNAs globally perturbs gene regulation by endog-
enous microRNAs. Nat. Biotechnol. 27:549–555. doi:10.1038/nbt.1543
Kimura, K., and S. Eguchi. 2009. Angiotensin II type-1 receptor regulates 
RhoA and Rho-kinase/ROCK activation via multiple mechanisms. Focus 
on “Angiotensin II induces RhoA activation through SHP2-dependent 
dephosphorylation of the RhoGAP p190A in vascular smooth muscle 
cells”. Am. J. Physiol. Cell Physiol. 297:C1059–C1061. doi:10.1152/ajpcell 
.00399.2009
Latronico, M.V., and G. Condorelli. 2009. MicroRNAs and cardiac pathology. 
Nat Rev Cardiol. 6:418–429. doi:10.1038/nrcardio.2009.56
Lee,  H.H.,  and  Z.F.  Chang.  2008.  Regulation  of  RhoA-dependent 
ROCKII activation by Shp2. J. Cell Biol. 181:999–1012. doi:10.1083/ 
jcb.200710187
Lee,  Y., X.  Yang,  Y. Huang, H. Fan, Q. Zhang,  Y. Wu, J. Li, R. Hasina, C. Cheng, 
M.W. Lingen, et al. 2010. Network modeling identifies molecular func-
tions targeted by miR-204 to suppress head and neck tumor metastasis. 
PLOS Comput. Biol. 6:e1000730. doi:10.1371/journal.pcbi.1000730
Li, B., L. Yang, J. Shen, C. Wang, and Z. Jiang. 2007. The antiproliferative   
effect of sildenafil on pulmonary artery smooth muscle cells is mediated   
via upregulation of mitogen-activated protein kinase phosphatase-1 and 
degradation of extracellular signal-regulated kinase 1/2 phosphorylation. 
Anesth. Analg. 105:1034–1041. doi:10.1213/01.ane.0000278736.81133.26
Li, J., X.L. Niu, and N.R. Madamanchi. 2008. Leukocyte antigen-related 
protein tyrosine phosphatase negatively regulates hydrogen peroxide- 
induced vascular smooth muscle cell apoptosis. J. Biol. Chem. 283:34260–
34272. doi:10.1074/jbc.M806087200
Macian, F. 2005. NFAT proteins: key regulators of T-cell development and 
function. Nat. Rev. Immunol. 5:472–484. doi:10.1038/nri1632
McMurtry, M.S., S.L. Archer, D.C. Altieri, S. Bonnet, A. Haromy, G. Harry, S. 
Bonnet, L. Puttagunta, and E.D. Michelakis. 2005. Gene therapy targeting 
survivin selectively induces pulmonary vascular apoptosis and reverses 
pulmonary arterial hypertension. J. Clin. Invest. 115:1479–1491. doi:10 
.1172/JCI23203
Mishra, P.K., N. Tyagi, M. Kumar, and S.C. Tyagi. 2009. MicroRNAs as a ther-
apeutic target for cardiovascular diseases. J. Cell. Mol. Med. 13:778–789. 
doi:10.1111/j.1582-4934.2009.00744.x
Naylor,  J.,  J.  Li,  C.J.  Milligan,  F.  Zeng,  P.  Sukumar,  B.  Hou, A.  Sedo,  N. 
Yuldasheva, Y. Majeed, D. Beri, et al. 2010. Pregnenolone sulphate- and 
cholesterol-regulated TRPM3 channels coupled to vascular smooth 
muscle secretion and contraction. Circ. Res. 106:1507–1515. doi:10.1161/ 
CIRCRESAHA.110.219329
Perros, F., D. Montani, P. Dorfmüller, I. Durand-Gasselin, C. Tcherakian, J. 
Le Pavec, M. Mazmanian, E. Fadel, S. Mussot, O. Mercier, et al. 2008. 
Platelet-derived  growth  factor  expression  and  function  in  idiopathic 
pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178:81–
88. doi:10.1164/rccm.200707-1037OC
Platoshyn, O.,  V.A. Golovina, C.L. Bailey, A. Limsuwan, S. Krick, M. Juhaszova, 
J.E. Seiden, L.J. Rubin, and J.X. Yuan. 2000. Sustained membrane depo-
larization and pulmonary artery smooth muscle cell proliferation. Am. J. 
Physiol. Cell Physiol. 279:C1540–C1549.
Rainio,  E.M.,  J.  Sandholm,  and  P.J.  Koskinen.  2002.  Cutting  edge: 
Transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase.  
J. Immunol. 168:1524–1527.
Rajkumar, R., K. Konishi, T.J. Richards, D.C. Ishizawar, A.C. Wiechert, 
N. Kaminski, and F. Ahmad. 2010. Genomewide RNA expression 
profiling in lung identifies distinct signatures in idiopathic pulmo-
nary  arterial  hypertension  and  secondary  pulmonary  hyperten-
sion. Am. J. Physiol. Heart Circ. Physiol. 298:H1235–H1248. doi:10 
.1152/ajpheart.00254.2009
Sakao, S., L. Taraseviciene-Stewart, J.D. Lee, K. Wood, C.D. Cool, and N.F. 
Voelkel. 2005. Initial apoptosis is followed by increased proliferation of 
apoptosis-resistant endothelial cells. FASEB J. 19:1178–1180.
Sato, K., T. Nagao, M. Kakumoto, M. Kimoto, T. Otsuki, T. Iwasaki, A.A. 
Tokmakov, K. Owada, and Y. Fukami. 2002. Adaptor protein Shc is an 
isoform-specific  direct  activator  of  the  tyrosine  kinase  c-Src.  J.  Biol. 
Chem. 277:29568–29576. doi:10.1074/jbc.M203179200
Arterioscler. Thromb. Vasc.  Biol.  30:716–723.  doi:10.1161/ATVBAHA 
.109.202028
Chen, X., H. Xu, P. Yuan, F. Fang, M. Huss, V.B. Vega, E. Wong, Y.L. Orlov, 
W. Zhang, J. Jiang, et al. 2008. Integration of external signaling path-
ways with the core transcriptional network in embryonic stem cells. Cell. 
133:1106–1117. doi:10.1016/j.cell.2008.04.043
Cheranov, S.Y., M. Karpurapu, D. Wang, B. Zhang, R.C. Venema, and G.N. 
Rao. 2008. An essential role for SRC-activated STAT-3 in 14,15-EET-
induced VEGF  expression  and  angiogenesis.  Blood.  111:5581–5591. 
doi:10.1182/blood-2007-11-126680
Christman, B.W., C.D. McPherson, J.H. Newman, G.A. King, G.R. Bernard, 
B.M. Groves, and J.E. Loyd. 1992. An imbalance between the excretion 
of thromboxane and prostacyclin metabolites in pulmonary hyperten-
sion. N. Engl. J. Med. 327:70–75. doi:10.1056/NEJM199207093270202
Cowan, K.N., P.L. Jones, and M. Rabinovitch. 2000. Elastase and matrix 
metalloproteinase  inhibitors  induce  regression,  and  tenascin-C  anti-
sense prevents progression, of vascular disease. J. Clin. Invest. 105:21–34. 
doi:10.1172/JCI6539
Doggrell,  S.A.  2005.  Rho-kinase  inhibitors  show  promise  in  pulmonary 
hypertension. Expert Opin. Investig. Drugs. 14:1157–1159. doi:10.1517/ 
13543784.14.9.1157
Dumas de la Roque, E., J.P. Savineau, and S. Bonnet. 2010. Dehydroepi-
androsterone: A new treatment for vascular remodeling diseases includ-
ing pulmonary arterial hypertension. Pharmacol. Ther. 126:186–199. doi:10 
.1016/j.pharmthera.2010.02.003
Dupuis, J., and M.M. Hoeper. 2008. Endothelin receptor antagonists in pul-
monary arterial hypertension. Eur. Respir. J. 31:407–415. doi:10.1183/ 
09031936.00078207
Ferracin, M., A. Veronese, and M. Negrini. 2010. Micromarkers: miRNAs 
in cancer diagnosis and prognosis. Expert Rev. Mol. Diagn. 10:297–308. 
doi:10.1586/erm.10.11
Fornaro, M., P.M. Burch, W. Yang, L. Zhang, C.E. Hamilton, J.H. Kim, B.G. 
Neel, and A.M. Bennett. 2006. SHP-2 activates signaling of the nuclear 
factor of activated T cells to promote skeletal muscle growth. J. Cell Biol. 
175:87–97. doi:10.1083/jcb.200602029
Frasch, H.F., C. Marshall, and B.E. Marshall. 1999. Endothelin-1 is elevated in 
monocrotaline pulmonary hypertension. Am. J. Physiol. 276:L304–L310.
Gharavi,  N.M.,  J.A. Alva,  K.P.  Mouillesseaux,  C.  Lai,  M. Yeh, W. Yeung,   
J. Johnson, W.L. Szeto, L. Hong, M. Fishbein, et al. 2007. Role of the 
Jak/STAT pathway in the regulation of interleukin-8 transcription by 
oxidized phospholipids in vitro and in atherosclerosis in vivo. J. Biol. 
Chem. 282:31460–31468. doi:10.1074/jbc.M704267200
Ghofrani, H.A., W. Seeger, and F. Grimminger. 2005. Imatinib for the treat-
ment of pulmonary arterial hypertension. N. Engl. J. Med. 353:1412–
1413. doi:10.1056/NEJMc051946
Glazova, M., T.L. Aho, A. Palmetshofer, A. Murashov, M. Scheinin, and P.J. 
Koskinen. 2005. Pim-1 kinase enhances NFATc activity and neuroen-
docrine functions in PC12 cells. Brain Res. Mol. Brain Res. 138:116–123. 
doi:10.1016/j.molbrainres.2005.04.003
Humbert, M., G. Monti, F. Brenot, O. Sitbon, A. Portier, L. Grangeot-
Keros, P. Duroux, P. Galanaud, G. Simonneau, and D. Emilie. 1995. 
Increased interleukin-1 and interleukin-6 serum concentrations in 
severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 
151:1628–1631.
Humbert, M., N.W. Morrell, S.L. Archer, K.R. Stenmark, M.R. MacLean, 
I.M. Lang, B.W. Christman, E.K. Weir, O. Eickelberg, N.F. Voelkel, and 
M.  Rabinovitch.  2004.  Cellular  and  molecular  pathobiology  of  pul-
monary arterial hypertension. J. Am. Coll. Cardiol. 43:S13–S24. doi:10 
.1016/j.jacc.2004.02.029
Ji, R., Y. Cheng, J. Yue, J. Yang, X. Liu, H. Chen, D.B. Dean, and C. Zhang.   
2007. MicroRNA expression signature and antisense-mediated depletion   
reveal  an  essential  role  of  MicroRNA  in  vascular  neointimal  lesion   
formation. Circ. Res. 100:1579–1588. doi:10.1161/CIRCRESAHA 
.106.141986
Jurasz, P., D. Courtman, S. Babaie, and D.J. Stewart. 2010. Role of apoptosis 
in pulmonary hypertension: from experimental models to clinical trials. 
Pharmacol. Ther. 126:1–8. doi:10.1016/j.pharmthera.2009.12.006
Katakami, N., H. Kaneto, H. Hao, Y. Umayahara, Y. Fujitani, K. Sakamoto, 
S. Gorogawa, T. Yasuda, D. Kawamori, Y. Kajimoto, et al. 2004. Role 548 miR-204 reverses pulmonary hypertension | Courboulin et al.
Shibata, R., H. Kai, Y. Seki, S. Kato, Y. Wada, Y. Hanakawa, K. Hashimoto, 
A. Yoshimura,  and T.  Imaizumi.  2003.  Inhibition  of  STAT3  prevents 
neointima formation by inhibiting proliferation and promoting apop-
tosis of neointimal smooth muscle cells. Hum. Gene Ther. 14:601–610. 
doi:10.1089/104303403321618128
Steiner, M.K., O.L. Syrkina, N. Kolliputi, E.J. Mark, C.A. Hales, and A.B. 
Waxman.  2009.  Interleukin-6  overexpression  induces  pulmonary   
hypertension.  Circ.  Res.  104:236–244.  doi:10.1161/CIRCRESAHA 
.108.182014
Steudel, W., F. Ichinose, P.L. Huang, W.E. Hurford, R.C. Jones, J.A. Bevan, 
M.C. Fishman, and W.M. Zapol. 1997. Pulmonary vasoconstriction and 
hypertension in mice with targeted disruption of the endothelial nitric 
oxide synthase (NOS 3) gene. Circ. Res. 81:34–41.
Stewart, D.J., R.D. Levy, P. Cernacek, and D. Langleben. 1991. Increased 
plasma endothelin-1 in pulmonary hypertension: marker or mediator of 
disease? Ann. Intern. Med. 114:464–469.
Tada, Y., S. Majka, M. Carr, J. Harral, D. Crona, T. Kuriyama, and J. West. 2007. 
Molecular effects of loss of BMPR2 signaling in smooth muscle in a 
transgenic mouse model of PAH. Am. J. Physiol. Lung Cell. Mol. Physiol. 
292:L1556–L1563. doi:10.1152/ajplung.00305.2006
Todorovich-Hunter,  L.,  D.J.  Johnson,  P.  Ranger,  F.W.  Keeley,  and  M. 
Rabinovitch. 1988. Altered elastin and collagen synthesis associated with 
progressive pulmonary hypertension induced by monocrotaline. A bio-
chemical and ultrastructural study. Lab. Invest. 58:184–195.
Tuder, R.M., J.C. Marecki, A. Richter, I. Fijalkowska, and S. Flores. 2007. 
Pathology of pulmonary hypertension. Clin. Chest Med. 28:23–42: vii. 
doi:10.1016/j.ccm.2006.11.010
Wang, F.E., C. Zhang, A. Maminishkis, L. Dong, C. Zhi, R. Li, J. Zhao, V. 
Majerciak, A.B.  Gaur,  S.  Chen,  and  S.S.  Miller.  2010.  MicroRNA-
204/211 alters epithelial physiology. FASEB J. 24:1552–1571. doi:10 
.1096/fj.08-125856
Wang, L., D. Xu, W. Dai, and L. Lu. 1999. An ultraviolet-activated K+ chan-
nel  mediates  apoptosis  of  myeloblastic  leukemia  cells.  J.  Biol.  Chem. 
274:3678–3685. doi:10.1074/jbc.274.6.3678
Wong, W.K., J.A. Knowles, and J.H. Morse. 2005. Bone morphogenetic pro-
tein receptor type II C-terminus interacts with c-Src: implication for 
a role in pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 
33:438–446. doi:10.1165/rcmb.2005-0103OC
Wu, J.H., R. Goswami, X. Cai, S.T. Exum, X. Huang, L. Zhang, L. Brian, R.T. 
Premont, K. Peppel, and N.J. Freedman. 2006. Regulation of the plate-
let-derived growth factor receptor-beta by G protein-coupled receptor 
kinase-5 in vascular smooth muscle cells involves the phosphatase Shp2. 
J. Biol. Chem. 281:37758–37772. doi:10.1074/jbc.M605756200
Yellaturu, C.R., and G.N. Rao. 2003. Cytosolic phospholipase A2 is an ef-
fector of Jak/STAT signaling and is involved in platelet-derived growth 
factor BB-induced growth in vascular smooth muscle cells. J. Biol. Chem. 
278:9986–9992. doi:10.1074/jbc.M211276200
Yildiz, P. 2009. Molecular mechanisms of pulmonary hypertension. Clin. 
Chim. Acta. 403:9–16. doi:10.1016/j.cca.2009.01.018
Yu, Y., M. Sweeney, S. Zhang, O. Platoshyn, J. Landsberg, A. Rothman, and 
J.X. Yuan. 2003. PDGF stimulates pulmonary vascular smooth muscle 
cell proliferation by upregulating TRPC6 expression. Am. J. Physiol. Cell 
Physiol. 284:C316–C330.
Yu, Y.,  I.  Fantozzi,  C.V.  Remillard,  J.W.  Landsberg,  N.  Kunichika,  O.  
Platoshyn, D.D. Tigno, P.A. Thistlethwaite, L.J. Rubin, and J.X. Yuan. 
2004. Enhanced expression of transient receptor potential channels in 
idiopathic pulmonary arterial hypertension. Proc. Natl. Acad. Sci. USA. 
101:13861–13866. doi:10.1073/pnas.0405908101
Yuan, X.J. 1995.  Voltage-gated K+ currents regulate resting membrane poten-
tial and [Ca2+]i in pulmonary arterial myocytes. Circ. Res. 77:370–378.
Zakrzewicz, A., M. Hecker, L.M. Marsh, G. Kwapiszewska, B. Nejman, L. 
Long, W. Seeger, R.T. Schermuly, N.W. Morrell, R.E. Morty, and O. 
Eickelberg. 2007. Receptor for activated C-kinase 1, a novel interaction 
partner of type II bone morphogenetic protein receptor, regulates smooth 
muscle cell proliferation in pulmonary arterial hypertension. Circulation. 
115:2957–2968. doi:10.1161/CIRCULATIONAHA.106.670026
Zhang, C. 2009. MicroRNA-145 in vascular smooth muscle cell biology: 
a new therapeutic target for vascular disease. Cell Cycle. 8:3469–3473. 
doi:10.4161/cc.8.21.9837
Zhao, L., R. al-Tubuly, A. Sebkhi, A.A. Owji, D.J. Nunez, and M.R. Wilkins. 
1996. Angiotensin II receptor expression and inhibition in the chroni-
cally hypoxic rat lung. Br. J. Pharmacol. 119:1217–1222.